Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kosan Biosciences has reported that the company will reduce its workforce by approximately 37% in order to focus resources on supporting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in non-small lung cancer.
Subscribe to our email newsletter
The restructuring will primarily affect the company’s research and administrative functions. As a result of the restructuring, most research programs will be placed on hold. The company may seek to partner these assets with companies looking for early-stage programs.
Helen Kim, Kosan’s CEO, said: “This represents an important step in Kosan’s evolution to a product-oriented company. We believe that this restructuring will strengthen our ability to effectively manage our resources, execute on our development goals and advance our high-value, near-term commercial opportunities.”